RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144-152

Eur J Cancer. 2017 May:77:21-23. doi: 10.1016/j.ejca.2017.02.019. Epub 2017 Mar 27.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • 3-Iodobenzylguanidine*
  • Humans
  • Incidence
  • Iodine Radioisotopes
  • Neoplasms, Second Primary
  • Neuroblastoma*
  • Radiopharmaceuticals
  • Risk Factors

Substances

  • Iodine Radioisotopes
  • Radiopharmaceuticals
  • 3-Iodobenzylguanidine